Ascendis Pharma A/S (NASDAQ:ASND)
| Market Cap | 14.09B+7.8% |
| Revenue (ttm) | 1.05B+114.8% |
| Net Income | 755.85M+378.8% |
| EPS | 11.45+342.1% |
| Shares Out | 62.11M |
| PE Ratio | 16.74 |
| Forward PE | 25.09 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,956.398 |
| Open | 227.83 |
| Previous Close | 228.41 |
| Day's Range | 226.30 - 227.98 |
| 52-Week Range | 186.05 - 282.15 |
| Beta | 0.37 |
| Analysts | Buy |
| Price Target | 317.42(+39.92%) |
| Earnings Date | Nov 11, 2026 |
Ascendis Pharma A/S has a live Insider Score.
Scored on 2 qualifying trades from 1 insider in the last 90 days.
About ASND
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ASND stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ASND holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ASND's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ASND Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ASND Revenue by Segment or Geography
Source: SEC EDGAR (10-Q/10-K)
U.S. Patents
New ASND patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ASND from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ASND
| ETF | Est. Holding Size |
|---|---|
| TCAFT. Rowe Capital Appreciation Equity ETF | $172.34M |
| IBBiShares Biotechnology ETF | $106.54M |
| IWPiShares Russell Mid-Cap Growth ETF | $64.67M |
| IWRiShares Russell Mid-Cap ETF | $50.23M |
| IWFiShares Russell 1000 Growth ETF | $43.11M |
| SQSSapient Quality Select ETF | $32.33M |
Estimated from each fund’s disclosed top holdings × AUM
ASND Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ASND’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score